Parabilis Medicines is ambitious, but it has Regeneron on its side already.

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Sofinnova Investments’ Jim Healy says biotech innovation is thriving but is skeptical about artificial intelligence’s ability ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.